Skip to contentM
Marimed Inc.
M
MRMDMarimed Inc. Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$31.04M$31.04Mderived+52.5% vs Q4 2020 Net Income-$6.51M-$6.51MderivedN/M vs Q4 2020 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Marimed Inc. · CIK 1522767 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$15,490,000+33.3% Operating Incomederived$1,203,000−85.0% Operating Cash Flowderived$7,607,000+328.8% Free Cash Flowderived$4,382,000+264.5% Margins · derivedGross margin49.9%−7.2 pt vs Q4 2020
Operating margin3.9%−35.6 pt vs Q4 2020
Net margin-21.0%−41.2 pt vs Q4 2020
ended Dec 31, 2021 · filed Mar 16, 2022 · 75 d after period end